India Biologics Market 2026-2034: Growth, Trends & Lucrative Opportunities Revealed

Introduction:

According to the latest research report titled "India Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2026-2034," the report offers a comprehensive analysis of the industry, including market share, growth, trends, and regional insights.

How Big is the India Biologics Market?

The India biologics market size was valued at USD 13.3 Billion in 2025 and is projected to reach USD 26.9 Billion by 2034, growing at a compound annual growth rate (CAGR) of 7.72% from 2026-2034. The market is growing notably, driven by government programs supporting biopharmaceutical research, innovations in biotechnology, and increasing need for advanced therapies.

Furthermore, the market benefits from rising healthcare investments, cost-efficient manufacturing capabilities, and a skilled labor force, positioning the region as a crucial player in the global biologics industry.

Evaluate Market Opportunity with the Business Sample Report: https://www.imarcgroup.com/india-biologics-market/requestsample

What are the Latest Emerging Trends in India Biologics Market?

• Rising Demand for Biosimilars

India's biologics market is witnessing a notable growth trajectory, mainly driven by increasing demand for biosimilars, fueled by their exceptional cost-efficiency. With patent expirations of major biologic drugs, Indian pharmaceutical firms are capitalizing on the opportunity to develop value-driven biosimilars for both international and domestic markets. For instance, in August 2024, Biocon Biologics signed a deal with Janssen Biotech Inc. to commercialize its biosimilar Bmab 1200 in major markets, including Canada and Europe. A strong manufacturing landscape and regulatory support further strengthen India's position as a key supplier of biosimilars.

• Government Support and Policy Initiatives

The Indian government's proactive policies are boosting the biologics market by promoting domestic manufacturing, research, and innovation. Initiatives such as "Make in India" and financial incentives for biotechnology firms are facilitating the development of biologic drugs. Regulatory frameworks are being upgraded to ensure faster approvals, incentivizing domestic companies to invest heavily in biologics. For instance, India's Biotechnology for Economy, Environment, and Employment (BioE3) policy was approved in 2024, following a remarkable tenfold expansion of the nation's bioeconomy, projected to reach USD 130 billion. The BioE3 initiative targets USD 300 billion by 2030.

• Advancements in Biomanufacturing Technologies

Technological innovations in biomanufacturing are transforming India's biologics industry, enabling the production of high-quality biologics at scale. Companies are adopting advanced techniques such as innovative cell culture technologies, single-use systems, and continuous bioprocessing to improve production efficiency. For instance, in July 2024, Bioserve India launched an innovative stem cell product line aimed at advancing drug design and research, fostering innovations in therapeutic development and regenerative medicine. Additionally, the integration of data analytics and artificial intelligence (AI) in biopharma operations is reducing costs and optimizing processes.

What Growth Factors are Driving India Biologics Market?

• Increasing Prevalence of Chronic Diseases

India's biologics market is being propelled by the rising demand for innovative therapies for the treatment of chronic diseases, including autoimmune disorders, cancer, and diabetes. According to the Press Information Bureau, India records around 800,000 new cancer cases annually, with tobacco-associated cancers accounting for 35%-50% of all cancer cases detected among men. This growing disease burden, combined with rising awareness of biologic treatments among patients and healthcare providers, is fueling market expansion.

• Technological Advancements and Manufacturing Growth

India's robust pharmaceutical landscape is rapidly investing in biologics manufacturing, leveraging cutting-edge expertise and facilities. As per industry reports, India accounted for 50% of the 8 billion vaccine doses distributed globally in 2023. Incentives and favorable regulatory frameworks for biosimilar and drug production are attracting both global and domestic players. The Production Linked Incentive (PLI) scheme, spanning 2022-2029, facilitated 89,545 million tons of production with an incentive outlay of INR 6,940 Cr.

• Rising Healthcare Investments and Infrastructure

Increasing healthcare budgets and the proliferation of healthcare infrastructure across India are supporting greater availability and utilization of biologics nationwide. Public-private collaborations and amplified funding for biopharma infrastructure are further boosting market growth, reinforcing India's position in the global pharmaceutical sector.

• Cost-Efficiency in Manufacturing

India's cost-efficient manufacturing capabilities, relative to other global regions, are establishing the nation as a crucial hub for biologics production, catering to both domestic and international demand while enhancing its global competitiveness.

How will the India Biologics Market Evolve in the Coming Years?

The India biologics market outlook remains highly promising, supported by strong policy backing, expanding manufacturing capabilities, and a growing disease burden requiring advanced therapeutic solutions. Government-led initiatives such as the BioE3 policy and the Production Linked Incentive scheme are creating a structured environment for sustained growth in biologics research, development, and production.

The market was valued at USD 13.3 Billion in 2025 and is projected to reach USD 26.9 Billion by 2034, expanding at a CAGR of 7.72% during 2026-2034. This growth trajectory is underpinned by rising biosimilar adoption, increased investments in biomanufacturing technologies, and favorable regulatory reforms. As India continues to strengthen its pharmaceutical ecosystem and global export capabilities, the biologics market is expected to witness accelerated expansion across therapeutic segments, reinforcing its long-term structural growth potential.

India Biologics Market Segmentation

Source Insights:

• Microbial
• Mammalian
• Others

Product Insights:

• Monoclonal Antibodies
• Vaccines
• Recombinant Proteins
• Antisense, RNAi and Molecular Therapy
• Others

Disease Insights:

• Oncology
• Immunological Disorders
• Cardiovascular Disorders
• Hematological Disorders
• Others

Manufacturing Insights:

• Outsourced
• In-House

Regional Insights:

• North India
• West and Central India
• South India
• East and Northeast India

Recent Developments & News:

• In May 2024, Serum Institute of India commenced exporting malaria vaccine R21/Matrix-M to Africa, with around 1.63 million doses allocated for the Central African Republic region.
• In May 2024, Serum Institute of India strategically acquired a 20% stake in IntegriMedical to enhance its needle-free injection system, aiming to improve patient adherence and minimize needle-stick injuries.
• In June 2024, Aurobindo Pharma collaborated with MSD to develop a biologics manufacturing plant in India, involving a significant investment of INR 1,000 Cr.

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant. Major players are expanding biosimilar production and leveraging biomanufacturing innovations to serve both domestic and international markets. Increased R&D investments, strategic partnerships, and public-private collaborations continue to drive market competition, while export opportunities position Indian manufacturers as key global suppliers.

Key Highlights of the Report

• Comprehensive analysis of the India biologics market size, share, and forecast through 2034.
• Detailed segmentation by source, product, disease, manufacturing, and region.
• Insights into market dynamics including growth drivers, restraints, and competitive landscape.
• Examination of government policies and initiatives impacting biologics market growth.
• Evaluation of technological trends and advancements in biomanufacturing.
• Coverage of recent partnerships, regulatory developments, and market expansions in the Indian biologics industry.

Get Custom Report Based on Your Interest: https://www.imarcgroup.com/request?type=report&id=biologics&flag=E

Customization Note: If you require any specific information not covered within this report's scope, we will provide it as part of the customization.

Frequently Asked Questions:

1. How large is the India biologics market?

➤ The India biologics market was valued at USD 13.3 Billion in 2025.

2. What is the expected growth rate of the market?

➤ The market is projected to grow at a CAGR of 7.72% from 2026 to 2034, reaching USD 26.9 Billion by 2034.

3. Which product segment leads the market?

➤ Monoclonal antibodies hold a substantial market share, driven by their efficacy in treating chronic diseases such as cancer, autoimmune disorders, and infectious diseases.

4. What factors are driving market growth?

➤ Growth is driven by rising chronic disease prevalence, government initiatives such as the BioE3 policy and PLI scheme, increasing biosimilar adoption, advancements in biomanufacturing technologies, and cost-efficient domestic production.

5. What are the key market challenges?

➤ Challenges include high development costs, complex regulatory requirements, the need for advanced manufacturing infrastructure, and intense global competition in the biosimilars space.

Get Sample of Our Latest In-Depth Reports On Related Topics:

✤ India Concierge Medicine Market: https://www.imarcgroup.com/india-concierge-medicine-market/requestsample

✤ Indian Diagnostic & Therapeutic Antibodies Market: https://www.imarcgroup.com/antibodies-market-india/requestsample

✤ India In Vitro Diagnostics Market: https://www.imarcgroup.com/india-in-vitro-diagnostics-market/requestsample

✤ India Digital Health Market: https://www.imarcgroup.com/india-digital-health-market/requestsample

Contact Us

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel: (D) +91 120 433 0800
United States: +1-201971-6302

About Us

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

This release was published on openPR.